Sopharma sells treasury shares on Bulgarian Stock Exchange

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

According to art. 17 of Regulation (EU) No 596/2014, “Sopharma” AD has disclosed the sale of treasury shares. On July 14, 2025, the company sold 17,000 repurchased own shares. These shares represent 0.01% of the company’s share capital and were sold at a total value of BGN 45,250.00 on the Bulgarian Stock Exchange, with an average price per share of BGN 2.66.

Following this transaction, Sopharma’s total number of treasury shares is now 8,875,963, which represents 4.94% of the company’s share capital.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.